GlobeNewswire Inc.··Equity-Insider.ComPatent Cliff Accelerates Biotech Rotation: Five Precision Oncology Firms Poised for Breakthrough
Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.
SNSEONCYTNGXOSTXATOSFDA approvalbiotech